NCT04120961View on ClinicalTrials.gov

Safety and Efficacy of Prolonged Use of Bivalirudin 4 Hours After ePCI (COBER Study)

NACompletedINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

September 20, 2019

Primary Completion Date

August 1, 2022

Study Completion Date

August 1, 2022

Conditions
Coronary Heart Disease
Interventions
DRUG

prolonged continuous use of bivalirudin

prolonged continuous use of bivalirudin 4 hours after elective PCI (dose: 0.75 mg/kg bolus plus 1.75 mg/kg per hour)

DRUG

bivalirudin use during ePCI

bivalirudin use during ePCI (0.75 mg/kg bolus plus 1.75 mg/kg per hour)

Trial Locations (1)

210006

Nanjing First Hospital, Nanjing Medical University, Nanjing

All Listed Sponsors
lead

Nanjing First Hospital, Nanjing Medical University

OTHER

NCT04120961 - Safety and Efficacy of Prolonged Use of Bivalirudin 4 Hours After ePCI (COBER Study) | Biotech Hunter | Biotech Hunter